Studies from the group
(1) Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009 May 7;113(19):4497-504.NordCML001
(2) Simonsson B, Gedde-Dahl T, Markevarn B, Remes K, Stentoft J, Almqvist A, et al. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011 Sep 22;118(12):3228-35. NordCML002
(3) Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Rasanen A, et al. Imatinib and pegylated IFN-alpha2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Eur J Haematol 2014;92(5):413-20. NordCML004
(4) Hjorth-Hansen H, Stenke L, Soderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol 2015 Mar;94(3):243-50.NordCML006
(5) Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia 2013 Jul;27(7):1520-6. NordCML006
NordCML007: Dasatinib + pegylated interferon alpha 2a (PegIntron). Phase 1b/II study of patients from diagnosis of CML Fully included May 2014. An abstract has been submitted for ASH2015
NordDutchCML009: Nilotinib +pegylated interferon alpha 2a (pegIntron) Phase 2 study of patients treated with imatinib for > 2years without achieving MR4.0. This study recruits slowly.
EuroSKI (NordCML008): Discontinuation study for patients in MR4.0 or better, which was fully recruited in 2013. Follow-up is ongoing. Abstracts were presented at ASH 2014 and EHA 2015.
NordCML010: Lab studies in stem cell and lymphocyte biology. Patients were recruited from the clinical study BFORE, a study ran by the company Avillion. Patients were treated from diagnosis in a randomized fashion with either imatinib or bosutinib, both 400mg OD. The clinical study was fully included in August 2015. Follow-up is ongoing.
New study protocols: Always in development. The group welcomes suggestions for cooperation Contact the chairman or secretary (see heading “About” for contact details)